Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04865289
Other study ID # 7902-001 China Extension
Secondary ID MK-7902-001ENGOT
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date October 22, 2019
Est. completion date April 10, 2025

Study information

Verified date February 2024
Source Merck Sharp & Dohme LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS). As of Amendment 7 eligible participants on study completion will be able to transition to an extension study, if available, in which they can continue to receive pembrolizumab monotherapy, lenvatinib monotherapy, or a combination of both pembrolizumab and lenvatinib as received in the parent study.


Description:

This China extension study will include participants previously enrolled in China in the global study for MK-7902-001 (NCT03884101) plus those enrolled during the China extension enrollment period.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 130
Est. completion date April 10, 2025
Est. primary completion date October 2, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Has Stage III, Stage IV, or recurrent, histologically-confirmed endometrial carcinoma with disease that is either measurable or nonmeasurable but radiographically apparent, per RECIST 1.1 as assessed by BICR (note: may have received prior chemotherapy only if administered concurrently with radiation; may have received prior radiation without concurrent chemotherapy; may have received prior hormonal therapy for treatment of endometrial carcinoma, provided that it was discontinued =1 week prior to randomization; and may have received 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy) - Has provided archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion that was not previously irradiated, for determination of mismatch repair (MMR) status - Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, as assessed within 7 days prior to the first dose of study intervention - Is not pregnant or breastfeeding, and is either not a woman of childbearing potential (WOCBP) or is a WOCBP who agrees to use contraception during the study and for =120 days after pembrolizumab, =30 days after lenvatinib, or =180 days after (chemotherapy) [if a WOCBP, a pregnancy test will be required within 24 hours of first dose of study drug] - Has adequately controlled blood pressure within 7 days prior to randomization - Has adequate organ function based on assessment within 7 days prior to the first dose of study intervention Exclusion Criteria: - Has carcinosarcoma (malignant mixed Mullerian tumor), endometrial leiomyosarcoma or other high grade sarcomas, or endometrial stromal sarcomas - Has a central nervous system (CNS) metastasis, unless local therapy (e.g., whole brain radiation therapy, surgery, or radiosurgery) has been completed and have discontinued use of corticosteroids for this indication for =4 weeks prior to starting study medication (major surgery within 3 weeks of the first dose of study drug will be exclusionary) - Has a known additional malignancy (other than endometrial carcinoma) that is progressing or has required active treatment in the last 3 years - Has gastrointestinal malabsorption or any other condition that might affect the absorption of lenvatinib - Has a pre-existing Grade =3 gastrointestinal or nongastrointestinal fistula - Has radiographic evidence of major blood vessel invasion/infiltration - Has active hemoptysis (bright red blood of =0.5 teaspoon) within 3 weeks prior to the first dose of study intervention, or tumor bleeding within 2 weeks prior to randomization - Has clinically significant cardiovascular disease within 12 months from first dose of study intervention including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, cerebral vascular accident, or cardiac arrhythmia associated with hemodynamic instability - Has any infection requiring systemic treatment - Has not recovered adequately from any toxicity and/or complications from major surgery prior to randomization - Has a known history of human immunodeficiency virus (HIV) infection (HIV test is required at screening) - Has a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (hepatitis B and C testing is required at screening) - Has a history of (noninfectious) pneumonitis that required treatment with steroids, or has current pneumonitis - Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator - Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study - Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization - Has an active autoimmune disease (with the exception of psoriasis) that has required systemic treatment in the past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs) - Has received prior systemic chemotherapy in any setting for the treatment of endometrial carcinoma (note: prior chemotherapy administered concurrently with radiation is permitted) - Has received prior radiotherapy within 4 weeks prior to randomization (participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis - a 2-week washout is permitted for palliative radiation to non-CNS disease and vaginal brachytherapy) - Has received prior hormonal therapy for the treatment of endometrial carcinoma within 1 week of randomization - Has received prior therapy with any treatment targeting vascular endothelial growth factor (VEGF)-directed angiogenesis, an anti-programmed cell death (PD)-1, anti-PD ligand (L)1, or anti-PD L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137) - Has received a live or live attenuated vaccine within 30 days prior to the first dose of study intervention - Has known intolerance to study intervention (or any of the excipients) - Has had an allogenic tissue/solid organ transplant - Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to randomization

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lenvatinib
Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.
Biological:
Pembrolizumab
Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.
Drug:
Paclitaxel
Paclitaxel 175 mg/m^2 IV infusion given on Day 1 of each cycle.
Carboplatin
Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.

Locations

Country Name City State
China Beijing Cancer Hospital ( Site 2504) Beijing Beijing
China Beijing Obstetrics and Gynecology Hospital Capital Medical University ( Site 2505) Beijing Beijing
China Peking Union Medical College Hospital ( Site 2501) Beijing Beijing
China The First Hospital Of Jilin University ( Site 2518) Changchun Jilin
China Hunan Cancer Hospital ( Site 2523) Changsha Hunan
China Xiangya Hospital Central-South University ( Site 2512) Changsha Hunan
China Chongqing Cancer Hospital ( Site 2513) Chongqing Chongqing
China The First Affiliated Hospital.Sun Yat-sen University ( Site 2507) Guangzhou Guangdong
China Women s Hospital School of Medicine Zhejiang University ( Site 2511) Hangzhou Zhejiang
China Zhejiang Cancer Hospital ( Site 2506) Hangzhou Zhejiang
China Harbin Medical University Cancer Hospital ( Site 2520) Harbin Heilongjiang
China Anhui Cancer Hospital-Gynecological Oncology ( Site 2509) Hefei Anhui
China Jiangxi Maternal and Child Health Hospital ( Site 2519) Nanchang Jiangxi
China Nanjing Maternity and Child Health Care Hospital ( Site 2508) Nanjing Jiangsu
China Guang Xi Tumour Hospital, Department of Chemotherapy ( Site 2517) Nanning Guangxi
China Fudan University Shanghai Cancer Center ( Site 2500) Shanghai Shanghai
China Obstetrics and Gynecology Hosp. Fudan University ( Site 2503) Shanghai Shanghai
China Shanghai First Maternity and Infant Hospital ( Site 2524) Shanghai Shanghai
China The First Affiliated Hospital of Xinjiang Medical University ( Site 2515) Urumqi Xinjiang
China Hubei Cancer Hospital ( Site 2510) Wuhan Hubei
China The first affiliated Hospital of Xi an Jiaotong University ( Site 2502) XI An Shaanxi
China The First Affiliated hospital of Xiamen University-Obstetrics and gynecology department ( Site 2522) Xiamen Fujian

Sponsors (2)

Lead Sponsor Collaborator
Merck Sharp & Dohme LLC Eisai Inc.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression-free survival (PFS) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) Progression-free survival based on RECIST 1.1 as assessed by BICR. Progression-free survival is measured from the time of randomization to the first documented disease progression or death due to any cause, whichever occurs first. Up to approximately 31 months
Primary Overall Survival (OS) Overall survival is measured from the time of randomization up to death due to any cause. Up to approximately 45 months
Secondary Objective response rate (ORR ) based on Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by blinded independent review (BICR) The ORR (either confirmed complete response [CR] or partial response [PR]) based on RECIST 1.1 and assessed by BICR will be determined in mismatch repair proficient (pMMR) participants and in all-comer participants who have measurable disease at study entry. Up to approximately 31 months
Secondary Change from baseline in the global score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core-30 (QLQ-C30) in pMMR and in all-comer participants The EORTC QLQ-C30 was developed to assess the quality of life of patients with cancer. It contains 30 questions (items), 24 of which aggregate into nine multi-item scales representing various aspects, or dimensions, of quality of life (QoL): one global scale, five functional scales (physical, role, cognitive, emotional, and social), 3 symptom scales (fatigue, nausea, pain), and six additional single-symptom items assessing additional symptoms commonly reported by cancer patients (dyspnoea, loss of appetite, insomnia, constipation and diarrhoea) and perceived financial impact of the disease. Individual items are scored on a 4-point scale (1=not at all, 2=a little, 3=quite a bit, 4=very much). Raw scores for each scale are standardized into a range of 0 to 100 by linear transformation; a higher score on the global and functional scales represents a higher ("better") level of functioning, and a higher score on the symptom scale represents a higher ("worse") level of symptoms. Baseline and designated time points up to 27 months
Secondary Percentage of participants experiencing an adverse event (AE) An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. Up to approximately 27 months (through 90 days after the last dose of study treatment)
Secondary Percentage of participants experiencing a serious adverse event (SAE) An SAE is an AE that results in death, is life-threatening, requires or prolongs hospitalization, results in persistent or significant disability, is a congenital birth defect, or is another important medical event. Up to approximately 28 months (through 120 days after the last dose of study treatment)
Secondary Percentage of participants experiencing an immune-related AE (irAE) Immune-related AEs will be monitored in both arms. Up to approximately 27 months (through 90 days after the last dose of study treatment)
Secondary Percentage of participants discontinuing from study treatment due to an AE(s) Discontinuations related to AEs will be monitored in both arms. Up to approximately 24 months (through the last dose of study treatment)
See also
  Status Clinical Trial Phase
Completed NCT02865889 - Cost-Effectiveness and Patients Satisfaction of Conventional vs Robotic-Assisted Laparoscopy in Gynecologic Oncologic Indications N/A
Completed NCT00377520 - A Trial for Patients With Advanced/Recurrent Endometrial Cancer Phase 2
Recruiting NCT05007106 - MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Phase 1/Phase 2
Active, not recruiting NCT05682950 - Optimal Margin Evaluation of Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Phase 2
Not yet recruiting NCT05974995 - Robotic-assisted Versus Conventional Laparoscopic Surgery in Obese Patients With Early Endometrial Cancer N/A
Recruiting NCT03291106 - Study of Universal Screening for Lynch Syndrome in Chinese Patients of Endometrial Cancer
Recruiting NCT03291275 - Survival Outcomes of Uterine Malignancies in Chinese Population N/A
Completed NCT00341458 - Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions With Genetics
Terminated NCT05067972 - A Study of PF-07260437 in Advanced or Metastatic Solid Tumors Phase 1
Recruiting NCT05795244 - Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC) Phase 2
Recruiting NCT05770102 - DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Phase 2/Phase 3
Completed NCT03270995 - Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study N/A
Terminated NCT01969396 - Evaluation of the Goldstein SonoBiopsy™ Catheter for Diagnosing Endometrial Pathology N/A
Completed NCT01460979 - Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma Phase 2
Active, not recruiting NCT05869123 - Online Adaptive Radiotherapy for Postoperative Treatment of Endometrial and Cervical Cancer Phase 1/Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Active, not recruiting NCT05588076 - Endometrial Lesions Predictions
Active, not recruiting NCT03935282 - Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors N/A
Completed NCT01717391 - [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Phase 2